This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Data availability
The participants of this study did not give written consent for their data to be shared publicly, so due to the sensitive nature of the research supporting data is not available.
References
Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37:677–87.
O’Neill AT, Chakraverty R. Graft Versus Leukemia: Current Status and Future Perspectives. J Clin Oncol. 2021;39:361–72.
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8.
Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematology Am Soc Hematol Educ Program. 2021;2021:254–63.
Fuji S, Hakoda A, Kanda J, Murata M, Terakura S, Inamoto Y, et al. Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021;56:2990–6.
Holtan SG, MacMillan ML. A risk-adapted approach to acute GVHD treatment: are we there yet? Bone Marrow Transplant. 2016;51:172–5.
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53:1401–15.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10.
Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, et al. Improved accuracy of acute graft-versus-host disease staging among multiple centers. Best Pract Res Clin Haematol. 2014;27:283–7.
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–8.
Fuji S, Kurosawa S, Inamoto Y, Nakano N, Miyazaki Y, Miyashita K, et al. Does an increased probability of graft-vs-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model. Advances in Cell and Gene Therapy 2019;2:e56.
Acknowledgements
The authors thank the medical, nursing, data processing, laboratory, and clinical staff members at the participating centers for their important contributions to this study and their dedicated patent care. This work was supported by a grant from the Practical Research for Innovative Cancer Control program of the Japan Agency for Medical Research and Development (22ck0106616h0003).
Author information
Authors and Affiliations
Contributions
SF, YI, JM, and MY designed the study, performed the analyses, and wrote the manuscript. NN, AI, TK, TE, SY, HI, YS, YM, NU, SM, OM, KI, TF, and YA were involved in the acquisition of the analyzed data. All the authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
SF received honoraria from Takeda Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, and Kyowa Kirin. YA received honoraria from Meiji Seika Pharma, JCR Pharmaceuticals, Novartis Pharma, Kyowa Kirin, AbbVie GK, and Astellas Pharma. MY received honoraria from Takeda Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, and Daiichi-Sankyo.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Fuji, S., Inoue, Y., Makiyama, J. et al. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia–lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant 58, 729–731 (2023). https://doi.org/10.1038/s41409-023-01969-7
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41409-023-01969-7